TARS Tarsus Pharmaceuticals
- 34.040
- -3.310-8.86%
- 34.550
- +0.510+1.50%
Tarsus Pharmaceuticals News
Tarsus Pharmaceuticals Q1 2024 GAAP EPS $(1.01) Beats $(1.20) Estimate, Sales $27.614M Beat $17.460M Estimate
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.20) by 15.83 percent. This is a 14.77 percent decrease over losses
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Oppenheimer: The Tarsus Pharmaceuticals (TARS.US) rating was maintained, and the target price was adjusted from better than the market to the superior market rating, and the target price was adjusted from $59.00 to $61.00.
Oppenheimer: The Tarsus Pharmaceuticals (TARS.US) rating was maintained, and the target price was adjusted from better than the market to the superior market rating, and the target price was adjusted from $59.00 to $61.00.
Tarsus Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 70.36% Oppenheimer $59 → $61 Maintains Outperform 03/06/2024 22.88% Jefferies $30 → $44 Maintai
Earnings Call Summary | Tarsus Pharmaceuticals(TARS.US) Q1 2024 Earnings Conference
The following is a summary of the Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript:Financial Performance:Tarsus reported $27.6 million in total revenue, made up of $24.7 million in
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating
Tarsus Pharmaceuticals (TARS) has an average rating of Buy and price targets ranging from $30 to $67, according to analysts polled by Capital IQ. Price: 35.83, Change: -1.52, Percent Change: -4.07
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator,
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Tarsus Pharmaceuticals | 10-Q: Quarterly report
Tarsus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Tarsus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q1 Revenue $27.6M, Vs. Street Est of $17.9M
04:16 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q1 Revenue $27.6M, vs. Street Est of $17.9M
Press Release: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Generated $24.7 million in net product sales of XDEMVY(R) , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients .
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals
BioPharma Credit (BPCR.L) and BioPharma Credit Investments V signed a definitive senior-secured loan deal to each invest up to $100 million in US-based Tarsus Pharmaceuticals. The life sciences debt i
Tarsus Pharmaceuticals Secures $75M Loan for Growth and Debt Repayment
Tarsus Strengthens Financial Position And Refinances Existing Debt With $200M Non-dilutive Financing Commitment From Pharmakon
Tarsus Strengthens Financial Position And Refinances Existing Debt With $200M Non-dilutive Financing Commitment From Pharmakon
Positive Signs As Multiple Insiders Buy Tarsus Pharmaceuticals Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), that sends out
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 912K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 11, $Tarsus Pharmaceuticals(TARS.US)$ Insider Trevejo Jose M. intends to sell 24,000 shares of its common stock on Apr 11, with a total market value of approximately $912K.
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
Analysis
Price Target
No Data
